vs
Side-by-side financial comparison of Edwards Lifesciences (EW) and Xylem Inc. (XYL). Click either name above to swap in a different company.
Xylem Inc. is the larger business by last-quarter revenue ($2.1B vs $1.6B, roughly 1.3× Edwards Lifesciences). Edwards Lifesciences runs the higher net margin — 23.1% vs 8.9%, a 14.2% gap on every dollar of revenue. On growth, Edwards Lifesciences posted the faster year-over-year revenue change (16.7% vs 2.7%). Over the past eight quarters, Edwards Lifesciences's revenue compounded faster (9.7% CAGR vs -1.0%).
Edwards Lifesciences Corporation is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring. It developed the Sapien transcatheter aortic heart valve made of cow tissue within a balloon-expandable, cobalt-chromium frame, deployed via catheter.
Xylem is one of the two types of transport tissue in vascular plants, the other being phloem; both of these are part of the vascular bundle. The basic function of the xylem is to transport water upward from the roots to parts of the plants such as stems and leaves, but it also transports nutrients. The word xylem is derived from the Ancient Greek word ξύλον (xúlon), meaning "wood"; the best-known xylem tissue is wood, though it is found throughout a plant.
EW vs XYL — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.6B | $2.1B |
| Net Profit | $380.7M | $189.0M |
| Gross Margin | 78.0% | 37.8% |
| Operating Margin | 1.8% | 11.5% |
| Net Margin | 23.1% | 8.9% |
| Revenue YoY | 16.7% | 2.7% |
| Net Profit YoY | 6.8% | 100.0% |
| EPS (diluted) | $0.66 | $0.79 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.6B | $2.1B | ||
| Q4 25 | $1.6B | $2.4B | ||
| Q3 25 | $1.6B | $2.3B | ||
| Q2 25 | $1.5B | $2.3B | ||
| Q1 25 | $1.4B | $2.1B | ||
| Q4 24 | $1.4B | $2.3B | ||
| Q3 24 | $1.4B | $2.1B | ||
| Q2 24 | $1.4B | $2.2B |
| Q1 26 | $380.7M | $189.0M | ||
| Q4 25 | $91.2M | $335.0M | ||
| Q3 25 | $291.1M | $227.0M | ||
| Q2 25 | $333.2M | $226.0M | ||
| Q1 25 | $358.0M | $169.0M | ||
| Q4 24 | $385.6M | $326.0M | ||
| Q3 24 | $3.1B | $217.0M | ||
| Q2 24 | $366.3M | $194.0M |
| Q1 26 | 78.0% | 37.8% | ||
| Q4 25 | 78.1% | 38.9% | ||
| Q3 25 | 77.8% | 38.9% | ||
| Q2 25 | 77.5% | 38.8% | ||
| Q1 25 | 78.7% | 37.1% | ||
| Q4 24 | 78.9% | 38.0% | ||
| Q3 24 | 80.6% | 37.3% | ||
| Q2 24 | 79.9% | 37.8% |
| Q1 26 | 1.8% | 11.5% | ||
| Q4 25 | 9.6% | 14.7% | ||
| Q3 25 | 19.8% | 14.7% | ||
| Q2 25 | 26.8% | 13.3% | ||
| Q1 25 | 27.9% | 11.2% | ||
| Q4 24 | 22.6% | 11.8% | ||
| Q3 24 | 25.9% | 13.3% | ||
| Q2 24 | 26.8% | 11.7% |
| Q1 26 | 23.1% | 8.9% | ||
| Q4 25 | 5.8% | 14.0% | ||
| Q3 25 | 18.7% | 10.0% | ||
| Q2 25 | 21.7% | 9.8% | ||
| Q1 25 | 25.3% | 8.2% | ||
| Q4 24 | 27.8% | 14.5% | ||
| Q3 24 | 226.7% | 10.3% | ||
| Q2 24 | 26.7% | 8.9% |
| Q1 26 | $0.66 | $0.79 | ||
| Q4 25 | $0.16 | $1.37 | ||
| Q3 25 | $0.50 | $0.93 | ||
| Q2 25 | $0.56 | $0.93 | ||
| Q1 25 | $0.61 | $0.69 | ||
| Q4 24 | $0.65 | $1.33 | ||
| Q3 24 | $5.13 | $0.89 | ||
| Q2 24 | $0.61 | $0.80 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $808.0M |
| Total DebtLower is stronger | — | $1.9B |
| Stockholders' EquityBook value | — | $11.0B |
| Total Assets | — | $17.0B |
| Debt / EquityLower = less leverage | — | 0.18× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $808.0M | ||
| Q4 25 | $4.2B | $1.5B | ||
| Q3 25 | $3.8B | $1.2B | ||
| Q2 25 | $4.1B | $1.2B | ||
| Q1 25 | $3.9B | $1.1B | ||
| Q4 24 | $4.0B | $1.1B | ||
| Q3 24 | $4.4B | $989.0M | ||
| Q2 24 | $2.0B | $815.0M |
| Q1 26 | — | $1.9B | ||
| Q4 25 | — | $2.0B | ||
| Q3 25 | — | $2.0B | ||
| Q2 25 | — | $2.0B | ||
| Q1 25 | — | $2.0B | ||
| Q4 24 | — | $2.0B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $11.0B | ||
| Q4 25 | $10.3B | $11.5B | ||
| Q3 25 | $10.2B | $11.2B | ||
| Q2 25 | $10.5B | $11.1B | ||
| Q1 25 | $10.1B | $10.8B | ||
| Q4 24 | $10.0B | $10.6B | ||
| Q3 24 | $9.5B | $10.6B | ||
| Q2 24 | $7.4B | $10.3B |
| Q1 26 | — | $17.0B | ||
| Q4 25 | $13.7B | $17.6B | ||
| Q3 25 | $13.3B | $17.3B | ||
| Q2 25 | $13.5B | $17.2B | ||
| Q1 25 | $13.0B | $16.6B | ||
| Q4 24 | $13.1B | $16.5B | ||
| Q3 24 | $13.0B | $16.0B | ||
| Q2 24 | $10.1B | $15.8B |
| Q1 26 | — | 0.18× | ||
| Q4 25 | — | 0.17× | ||
| Q3 25 | — | 0.18× | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.19× | ||
| Q4 24 | — | 0.19× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EW
Segment breakdown not available.
XYL
| Revenue from products | $1.8B | 83% |
| Revenue from services | $368.0M | 17% |
